SCHEMBL26646891

SCHEMBL26646891

COc1cc(S(=O)(=O)C2CC2)cnc1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 3/20 0.37
▸ LOXL2 Q9Y4K0 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ MAP3K11 Q16584 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ GABRA2 P47869 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ MMP13 P45452 1/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35
▸ PDE4D Q08499 1/20 0.35
▸ SHMT2 P34897 1/20 0.34
▸ CYP17A1 P05093 1/20 0.34
▸ TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30828948 1.00 FYN (0.37) FYNLOXL2TP53MAP3K11POLB
SCHEMBL23625227 0.85 FYN (0.36) FYNLOXL2TP53MAP3K11POLB
SCHEMBL26975286 0.80 NOS3 (0.44) AKT1PIK3CAMTOR
SCHEMBL30068268 0.79 FYN (0.50) FYNLOXL2TP53POLBKCNH2
SCHEMBL26646776 0.79 FYN (0.50) FYNLOXL2TP53POLBKCNH2
SCHEMBL26646913 0.76 FYN (0.39) FYNLOXL2TP53POLBMEN1
SCHEMBL30829003 0.76 FYN (0.39) FYNLOXL2TP53POLBMEN1
SCHEMBL30068131 0.75 FYN (0.39) FYNLOXL2TP53POLBGABRA2
SCHEMBL28843968 0.75 MAPT (0.49) TP53POLBMMP13PDE4APDE4B
SCHEMBL26647445 0.75 MAPT (0.50) FYNTP53POLBKMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 — — US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 — — US disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 — — CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 — — EP disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
WO-2022240876-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2022-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 FYN 647/4885LOXL2 1259/4885TP53 273/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 FYN 647/4885LOXL2 1259/4885TP53 273/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 FYN 647/4885LOXL2 1259/4885TP53 273/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 FYN 647/4885LOXL2 1259/4885TP53 273/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 FYN 664/4885LOXL2 1264/4885TP53 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback